These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 35551240)

  • 1. Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy.
    Zhang D; Wang G; Yu X; Wei T; Farbiak L; Johnson LT; Taylor AM; Xu J; Hong Y; Zhu H; Siegwart DJ
    Nat Nanotechnol; 2022 Jul; 17(7):777-787. PubMed ID: 35551240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components.
    Kazemian P; Yu SY; Thomson SB; Birkenshaw A; Leavitt BR; Ross CJD
    Mol Pharm; 2022 Jun; 19(6):1669-1686. PubMed ID: 35594500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of lipid Nanoparticle-Mediated delivery of CRISPR-Cas9 RNP versus mRNA/sgRNA for gene editing in vitro and in vivo.
    Walther J; Porenta D; Wilbie D; Seinen C; Benne N; Yang Q; de Jong OG; Lei Z; Mastrobattista E
    Eur J Pharm Biopharm; 2024 Mar; 196():114207. PubMed ID: 38325664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy.
    Rosenblum D; Gutkin A; Kedmi R; Ramishetti S; Veiga N; Jacobi AM; Schubert MS; Friedmann-Morvinski D; Cohen ZR; Behlke MA; Lieberman J; Peer D
    Sci Adv; 2020 Nov; 6(47):. PubMed ID: 33208369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of ionizable lipid nanoparticles and a lyophilized formulation for potent CRISPR-Cas9 delivery and genome editing.
    Sun Q; Zhang H; Ding F; Gao X; Zhu Z; Yang C
    Int J Pharm; 2024 Mar; 652():123845. PubMed ID: 38266942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-sgRNA CRISPR/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization.
    Fierro J; DiPasquale J; Perez J; Chin B; Chokpapone Y; Tran AM; Holden A; Factoriza C; Sivagnanakumar N; Aguilar R; Mazal S; Lopez M; Dou H
    Sci Rep; 2022 Feb; 12(1):2417. PubMed ID: 35165339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-based nanocarrier mediated CRISPR/Cas9 delivery for cancer therapy.
    Aziz A; Rehman U; Sheikh A; Abourehab MAS; Kesharwani P
    J Biomater Sci Polym Ed; 2023 Feb; 34(3):398-418. PubMed ID: 36083788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folate Receptor-Mediated Delivery of Cas9 RNP for Enhanced Immune Checkpoint Disruption in Cancer Cells.
    Lin Y; Wilk U; Pöhmerer J; Hörterer E; Höhn M; Luo X; Mai H; Wagner E; Lächelt U
    Small; 2023 Jan; 19(2):e2205318. PubMed ID: 36399647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing.
    Finn JD; Smith AR; Patel MC; Shaw L; Youniss MR; van Heteren J; Dirstine T; Ciullo C; Lescarbeau R; Seitzer J; Shah RR; Shah A; Ling D; Growe J; Pink M; Rohde E; Wood KM; Salomon WE; Harrington WF; Dombrowski C; Strapps WR; Chang Y; Morrissey DV
    Cell Rep; 2018 Feb; 22(9):2227-2235. PubMed ID: 29490262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A carrier-free multiplexed gene editing system applicable for suspension cells.
    Ju A; Lee SW; Lee YE; Han KC; Kim JC; Shin SC; Park HJ; EunKyeong Kim E; Hong S; Jang M
    Biomaterials; 2019 Oct; 217():119298. PubMed ID: 31280073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular Delivery of mRNA for Cell-Selective CRISPR/Cas9 Genome Editing using Lipid Nanoparticles.
    Ma T; Chen X; Wang M
    Chembiochem; 2023 May; 24(9):e202200801. PubMed ID: 36780174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Advances in LNP-CRISPR Therapeutics for Solid Tumor Treatment.
    Wang S; Zhu Y; Du S; Zheng Y
    Cells; 2024 Mar; 13(7):. PubMed ID: 38607007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea.
    Mirjalili Mohanna SZ; Djaksigulova D; Hill AM; Wagner PK; Simpson EM; Leavitt BR
    J Control Release; 2022 Oct; 350():401-413. PubMed ID: 36029893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of nucleic acid based genome editing platforms via lipid nanoparticles: Clinical applications.
    Masarwy R; Stotsky-Oterin L; Elisha A; Hazan-Halevy I; Peer D
    Adv Drug Deliv Rev; 2024 Aug; 211():115359. PubMed ID: 38857763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
    Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
    Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologically produced and metal-organic framework delivered dual-cut CRISPR/Cas9 system for efficient gene editing and sensitized cancer therapy.
    Yu J; Tang M; Zhou Z; Wei Z; Wan F; Hou S; Li Q; Li Y; Tian L
    Acta Biomater; 2024 Apr; 178():296-306. PubMed ID: 38417646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy.
    Han JP; Kim M; Choi BS; Lee JH; Lee GS; Jeong M; Lee Y; Kim EA; Oh HK; Go N; Lee H; Lee KJ; Kim UG; Lee JY; Kim S; Chang J; Lee H; Song DW; Yeom SC
    Sci Adv; 2022 Jan; 8(3):eabj6901. PubMed ID: 35061543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid.
    Tang Q; Liu J; Jiang Y; Zhang M; Mao L; Wang M
    ACS Appl Mater Interfaces; 2019 Dec; 11(50):46585-46590. PubMed ID: 31763806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: Advances in genome editing and CAR T cell therapy.
    Soroudi S; Jaafari MR; Arabi L
    J Control Release; 2024 Aug; 372():113-140. PubMed ID: 38876358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
    Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
    ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.